Literature DB >> 28554172

The Circulating MicroRNA-206 Level Predicts the Severity of Pulmonary Hypertension in Patients with Left Heart Diseases.

Peng Jin1, Wenzhu Gu1, Yayu Lai1, Wei Zheng1, Qi Zhou2, Xiaojing Wu1.   

Abstract

BACKGROUND: MicroRNA-206 (miR-206), a muscle-specific miRNA, regulates the growth of cardiac myocytes and pulmonary artery smooth muscle cells. However, it remains unknown whether miR-206 is involved in pulmonary hypertension (PH) due to left heart diseases (PH-LHD). This study was designed to investigate the correlation between miR-206 and PH in patients with LHD.
METHODS: In 82 consecutively enrolled LHD patients, we examined the serum levels of miR-206 and analyzed its correlations with pulmonary artery systolic pressure (PASP) and cardiac function. Another 36 age- and sex-matched subjects served as healthy controls.
RESULTS: The patients were divided into the LHD group (n=47, PASP<50 mmHg) and the PH-LHD group (n=35, PASP≥50 mmHg). The level of miR-206 was significantly decreased in the PH-LHD group compared with that of the LHD and healthy control groups. In addition, the miR-206 level was correlated with PASP (r=-0.305, p<0.001) but not with systemic blood pressure. Univariate analyses showed that miR-206, brain natriuretic peptide (BNP), left ventricular ejection fraction and left atrial longitudinal diameter (LAD) were significantly related to PASP. Multivariate regression analysis identified miR-206 as an independent predictive factor for PH. MiR-206 alone (cut-off <0.66) demonstrated a sensitivity of 68.60% and a specificity of 65.80% in predicting PH. Moreover, the combination of miR-206, BNP and LAD (cut-off 0.21) showed a sensitivity of 97.10% and a specificity of 80.30% in predicting PH in LHD patients.
CONCLUSION: A decreased circulating miR-206 level was associated with increased PASP in LHD patients. Thus, the level of miR-206, especially combined with BNP and LAD, might be helpful in the detection of PH in LHD patients.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Biomarker, microRNA; Heart failure; Left heart diseases; Pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28554172     DOI: 10.1159/000475569

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  13 in total

1.  miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.

Authors:  Chi Pang; Gang Huang; Kaili Luo; Yuying Dong; Fengtian He; Guankui Du; Man Xiao; Wangwei Cai
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

2.  miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.

Authors:  Jing Jiang; Yimeng Xia; Yi Liang; Meiling Yang; Wen Zeng; Xiaocong Zeng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-20

Review 3.  Noncoding RNAs in Hypertension.

Authors:  Amela Jusic; Yvan Devaux
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

Review 4.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

5.  Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension.

Authors:  Leonard E Estephan; Michael V Genuardi; Chad M Kosanovich; Michael G Risbano; Yingze Zhang; Nancy Petro; Annie Watson; Yassmin Al Aaraj; John C Sembrat; Mauricio Rojas; Dmitry A Goncharov; Marc A Simon; Elena A Goncharova; Anjali Vaidya; Akaya Smith; Jeremy Mazurek; Yuchi Han; Stephen Y Chan
Journal:  Pulm Circ       Date:  2019 Apr-Jun       Impact factor: 3.017

Review 6.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

Review 7.  A narrative review of the roles of the miR-15/107 family in heart disease: lessons and prospects for heart disease.

Authors:  Manni Zheng; Min Wang
Journal:  Ann Transl Med       Date:  2021-01

8.  Evaluation of the performance of serum miRNAs as normalizers in microRNA studies focused on cardiovascular disease.

Authors:  Xiaoyan Wang; Xiaoyi Zhang; Jie Yuan; Jian Wu; Xin Deng; Juan Peng; Shijun Wang; Chunjie Yang; Junbo Ge; Yunzeng Zou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  MicroRNA-204 as an Indicator of Severity of Pulmonary Hypertension in Children with Congenital Heart Disease Complicated with Pulmonary Hypertension.

Authors:  Xu Li; Daokang Xiang; Yizhu Shu; Kui Hu; Yongchun Zhang; Yonghong Li
Journal:  Med Sci Monit       Date:  2019-12-30

10.  The role of physical activity and miRNAs in the vascular aging and cardiac health of dialysis patients.

Authors:  Miroslava Rabajdova; Ivana Spakova; Aurel Zelko; Jaroslav Rosenberger; Peter Kolarcik; Vladimira Sobolova; Daniel Pella; Maria Marekova; Andrea Madarasova Geckova
Journal:  Physiol Rep       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.